Acclinate’s Expansion Signals Innovation in Digital Health

Acclinate, Inc,‘s recent announcement of plans to expand its workforce in Birmingham marks a pivotal moment for the Alabama-based digital health startup. This strategic move not only signifies growth but also a commitment to innovation in the field.

At the core of Acclinate’s success is its dedication to cutting-edge research and development. The company’s expansion aligns with recent groundbreaking discoveries and technological breakthroughs that position Acclinate as a trailblazer in the digital health sphere.

Acclinate’s mission centers around personalized medicine, tailored to the unique genetic makeup of individuals. Their research and development initiatives delve into genomics, seeking to decipher the genetic codes underlying various health conditions. By understanding these codes, Acclinate aims to pave the way for treatments and interventions optimized for individual patients.

In addition to this commitment, Acclinate is working to confront a systemic problem – the underrepresentation of people of color in clinical research. Their platform, NowIncluded, helps people of color take control of their health and encourages participation in clinical trials both digitally and in person.

“As we expand our presence in Birmingham, Acclinate remains committed to our mission of health equity through inclusive research,” said CEO and co-founder Del Smith, Ph.D.

With the project, Acclinate plans to expand its operation in the Denham Building in the city’s Parkside neighborhood and create 25 new jobs with an average annual salary of $83,000 over a three-year period, according to the Alabama Department of Commerce.

Key to Acclinate’s success is its commitment to collaborative innovation. Actively fostering partnerships with research institutions, healthcare providers, and tech innovators accelerates the pace of discovery and ensures that Acclinate remains at the forefront of advancements in digital health.

As Acclinate embarks on this transformative journey, the company is poised to play a pivotal role in shaping the future of healthcare. The intersection of technology, genomics, and personalized medicine holds immense promise, and Acclinate is at the forefront of harnessing these possibilities for the betterment of individuals and communities.

Acclinate’s strides in research and development underscore its commitment to innovation and position the company as a beacon of progress in the digital health landscape. With the addition of 25 new workers in Birmingham, Acclinate is set to amplify its impact, driving positive change and shaping the future of healthcare.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at or contact your usual Swanson Reed representative.

Recent Posts